

Meeting of the *London Cancer* Upper GI (OG) Pathway Board

Meeting to be held between 15:30 – 17:00 on Wednesday 12th April 2017, Boardroom, UCLH @ Westmoreland Street, 16-18 Westmoreland Street, London, W1G 8PH

Chair: **Prof Muntzer Mughal**

1. Welcome and introductions and Minutes from last meeting

MM welcomed members of the board, introductions were made and apologies heard. The minutes of the last Pathway Board were accepted as an accurate record with minor amendments made.

2. Board Priorities

- MM and JG will be visiting each LMDT within *London Cancer* to sit down and discuss the priorities of the pathway board. These visits will be starting in May 2017
- BH discussed board priorities from the patient perspective, and stated that there have not been many issues raised from the support groups across the region. These support groups include a variety of patients at different stages within their cancer treatment. There have been no issues raised in regards to access to hospital services.
- Patient awareness was raised as a potential priority for the board. CNS's from across the network have already been involved in campaigns. Evidence shows that national campaigns have a positive impact and shows an uptake in referrals during the campaign.
- At PAH 10% of diagnoses come from emergency care – this is something that needs to be addressed through public awareness and education.
- MM highlighted the up and coming breath test pilot that is being led by George Hanna. The testing of the equipment and technique has already been completed and the next stage of the pilot is to trial the test with 3000 patients in primary care. *London Cancer* will be a pilot centre for this new trial.
- Another priority raised by the board was the availability of PET CT scans for patients and where this fits into the pathway. MM felt that this is a decision that could be protocolised and therefore would not have to wait for the MDT decision. This is something that, the board will be looking to introduce in light of the recent MDT Improvement report from *London Cancer*. The SMDT are looking at ways to hold a preparation meeting in which 'straightforward' cases can be discussed prior to the MDT. This should streamline the pathway for these patients allowing more flexibility in the system.
- The board also felt it should be a priority to update guidelines for the network, focussing on SCC patients who are treated with radical chemo rad. SACT data should be able to provide morbidity and mortality rates for these patients.
- Barretts Surveillance dedicated lists were discussed by the board, the main issue is endoscopy capacity across the network. PAH has lost a nurse endoscopist who was running the Barretts Surveillance.
- Resource pressure across the network does not allow contained surveillance database and dedicated lists for these patients. MM highlighted that LCA (*London Cancer Alliance*) were able to gain a consensus and database started on Barretts Surveillance.

- RP raised an issue with the pathway for patients with high grade dysplasia and mentioned that the ops policy needs a pathway included for these patients. Previously, these patients were referred to the SMDT, however due to capacity issues; a separate MDT dedicated to high grade dysplasia was established. If invasive cancer was found then these would be fed into the SMDT as usual.
- This has reduced the demand on the SMDT but LMDTs are not receiving information back from this HGD meeting that is vital for cancer waiting times tracking.

ACTION: BH to ask patient support groups for any concerns that the pathway board should be made aware of and feedback at the next meeting.

**SH to pull morbidity and mortality rates for SCC patients who are treated with radical chemo rad
MM and JG to speak to RMPartners regarding LCA Barretts Surveillance Programme.**

3. Centre for Cancer Outcomes

- SH, senior analyst from the Centre for Cancer Outcomes presented the work being done around MDT balanced scorecards. These have been designed to improve the overall information and cancer outcomes across the *London Cancer* network. This piece of work is collaboration with the Vanguard partners.
- Initially these scorecards will be rolled out across UCLH MDTs with the aim to roll this out across the network. It will offer the ability for MDTs to see real time data information with an opportunity to change the data before it is sent to COSD. This aims to improve data collection across the network.
- The CCO (Centre for Cancer Outcomes) will be meeting with pathway boards to discuss tumour specific data that they would like to capture. This can then be incorporated to the balanced scorecard.

4. Dietetics

- AD presented the Oviva dietetics app. This is a digital based app that enables Dieticians to be more accessible to a larger number of patients. Currently this app is being used at GSTT trust for diabetes patients.
- RMPartners are in the process of trialling this for OG and Breast cancer patients.
- Patient feedback is very good however consideration needs to be made about how this would work for our network. The app allows 1 Dietician to manage 300 patients. This would require a band 7 specialist Dietician.
- This would allow Dieticians to work across more than one trust, and could cross cover each other, increasing the efficiency of the Dieticians.
- Issues were raised about elderly patients who may not have a smart phone, or able to use the app. Family members can have access to the app to help older patients.
- 90% of users have said they would recommend it to other patients
- Board decided that it would be beneficial to continue investigating the use of this app in the network. To begin with, need to understand current state of patient satisfaction at the moment, so that this can be measured. 3 month audit should be run.
- AD to continue conversations with the app developer, to involve a CNS and patient representative who can help develop the specifications for OG cancer patients.

ACTION: AD to send patient satisfaction audit to JG and MM to share with London Cancer network.

AD to set up a sub group including a CNS and patient representative to continue conversations

with Oviva.

5. Pan London OG Meeting

- A Pan London OG event will be held in December, focussing on training and education. This has been set up in collaboration with OG leads from across London and MM has been asked to organise.
- MM asked the board what topics they feel would be important to discuss and also if they knew of any speakers who could present at the event.
- The event will be a whole day event, the date and venue will be confirmed shortly.

ACTION: Board to feedback ideas to MM on Pan London OG event.

6. Cancer Outcomes

- MM presented the National OG data on cancer outcomes.

7. Update on MDT Improvement

- The MDT Improvement report, being led by Prof Muntzer Mughal, is currently being finalised and will be distributed within the next couple of weeks

8. AOB

Next meeting date: 12th July 2017, 15:30-17:00, Boardroom, UCLH @ Westmoreland Street, 16-18 Westmoreland Street, London, W1G 8PH

ACTION LOG

Action reference	Action	Owner	Date Due	Status
	AD to investigate app based support for Dietetics and feedback at next PBM.	AD	12/04/2017	completed
	AD to present outcomes data after 12 months. And to link in with CS regarding a comparison with PAH.	AD	12/07/2017	
	MM and JG to organise programme of visits to each MDT to discuss Board Priorities and Attendance	MM/JG	12/07/2017	On going
	BH to ask patient support groups for any concerns that the pathway board should be made aware of and feedback at the next meeting.	BH	12/07/2017	
	SH to pull morbidity and mortality rates for SCC patients who are treated with radical chemo rad	SH/CCO	12/07/2017	

	MM and JG to speak to RMPartners regarding LCA Barretts Surveillance Programme.	JG/MM	12/07/2017	
	AD to send patient satisfaction audit to JG and MM to share with London Cancer network.	AD	01/05/2017	
	AD to set up a sub group including a CNS and patient representative to continue conversations with Oviva.	AD	On going	
	Board to feedback ideas to MM on Pan London OG event.	ALL	01/05/2017	

Attendees

Name	Trust/Organisation
Prof Muntzer Mughal	UCLH Cancer Collaborative
Andrea Davis	Royal Free
Sean Hession	UCLH Cancer Collaborative
Martina Kelly	Homerton
Rosemary Phillips	Princess Alexandra
Jacob Goodman	UCLH Cancer Collaborative
Donna Hodge	Royal Free
Brian Hill	Patient Representative
Hemal Ariyaratne	Royal Free

Apologies

Name	Trust/Organisation
Andrew Millar	UCLH
Cate Simmons	PAH
David Holden	Patient Representative
Frances Hughes	Barts Health
George Hanna	Imperial
Rosemary Phillips	PAH
William McIntyre	UCLH